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Abstract Interleukin-9 (IL-9) stimulation results in JAK,
STAT and IRS1/2 phosphorylation. The role of IRS adaptor
proteins in IL-9 signaling is not clear. We show that IL-9 induces
IRS2 phosphorylation and association with phosphatidylinositol-
3 kinase (PI 3-K) p85 subunit in TS1 cells and BaF/9R cells,
which proliferate upon IL-9 stimulation. We observed a PI 3-K-
dependent phosphorylation of protein kinase B (PKB) in TS1
cells, but not in BaF/9R, nor in other IL-9-dependent cell lines.
Finally, 32D cells that were transfected with the IL-9 receptor
but lack IRS expression survived in the presence of IL-9. Ectopic
IRS1 expression allowed for IL-9-induced proliferation, in the
absence of significant PKB phosphorylation. ß 2000 Federa-
tion of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Interleukin-9 (IL-9) is secreted by T-helper lymphocytes
and has pleiotropic activities on mast cells, eosinophils, hem-
atopoietic progenitors, B- and T-lymphocytes [1,2]. In addi-
tion, IL-9 appears to play a role in certain murine and human
lymphomas [3]. This is supported by the ¢ndings that IL-9
transgenic mice develop thymic lymphomas [4]. Most recently,
genetic and functional studies have also implicated IL-9 and
its receptor in regulating susceptibility to asthma and allergy
[5^7].
The functional IL-9 receptor (IL-9R) consists of a hetero-
dimeric complex that comprised an K chain (IL-9RK), which
binds IL-9 ligand directly, and the IL-2RQC chain, which is a
common subunit of IL-2, IL-4, IL-7 and IL-15 receptor com-
plexes [8]. It is thought that, upon receptor ligation, the jux-
taposition of IL-9RK and IL-2RQC chains results in trans-
phosphorylation and activation of janus kinase (JAK) 1 and
JAK3, which are constitutively bound to each chain, respec-
tively. This event leads to phosphorylation of the tyrosine 367
in the cytoplasmic domain of the IL-9RK chain, which has
been reported to function as docking site for signal transducer
and activator transcription factor (STAT) 1, STAT3 and
STAT5 [9,10]. Subsequently, phosphorylated STAT molecules
dimerize and migrate to the nucleus where they bind regula-
tory sequences for de novo gene expression [11], thus regulat-
ing survival and proliferation mediated by IL-9 [9,12].
Insulin receptor substrate (IRS) proteins have been impli-
cated in cellular responses mediated by insulin, IGF-1 and
IL-4 [13]. IL-9 can induce phosphorylation of both IRS1
and IRS2 in various hematopoietic cells [9,14], including the
IL-9-dependent T-helper cell line TS1. The over-expression of
IRS1 in TS1 cells has been reported to enhance their prolif-
erative response to IL-9 [14], raising the possibility that
IRS1/2 could play a role in IL-9-dependent proliferation.
No data are available concerning downstream e¡ectors of
IRS1/2 function that are involved in IL-9 signaling.
Following JAK- or tyrosine receptor-mediated phosphory-
lation, IRS recruits signaling molecules containing Src homol-
ogy 2 domains, such as the regulatory subunit of phosphati-
dylinositol-3 kinase (PI 3-K) p85, causing the activation of the
PI 3-K catalytic subunit p110 [15]. The PI 3-K-mediated phos-
phorylation of phosphoinositide lipids triggers pleckstrin ho-
mology (PH) domain-mediated recruitment of protein kinase
B (PKB) to the plasma membrane where it becomes activated
via threonine and serine phosphorylation catalyzed by PDK1
[16] and by another yet undiscovered kinase referred to as
PDK2 [17]. PKB protects cells from caspase-mediated apopto-
sis by phosphorylating Bad, and preventing the release of
cytochrome c from mitochondria [18,19]. The PI 3-K/PKB
pathway appears to be involved in most of the signal trans-
duction processes that mediate cellular functions of di¡erent
cytokines, including IL-2, IL-3, IL-4, IL-6, IL-7, stem cell
factor (SCF) and PDGF [16,17].
With this study, we aimed to better de¢ne the role of IRS1/
2 and downstream e¡ectors in IL-9-elicited events involved in
survival and proliferative responses, using IRS-null 32D cells
and various cell lines that proliferate in response to IL-9.
2. Materials and methods
2.1. Cell culture and proliferation assay
TS1 cells were maintained in Dulbecco’s modi¢ed Eagle medium
(DMEM) (Gibco/BRL) containing 10% fetal bovine serum (FBS)
(Gibco/BRL), non-essential amino acids (Gibco/BRL), 5.5U1034 M
2-mercaptoethanol (Gibco/BRL) and 20 ng/ml of murine IL-9 (RpD
Systems). Ba/F3, 32D and MC9 cells were maintained in DMEM
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containing 10% FBS with the addition of 10 ng/ml of murine IL-3,
whereas Mo7e cells were maintained in the presence of human IL-3
(hIL-3) (RpD Systems).
2.2. Transfection and plasmids
Baf/9R is a cell line expressing the hIL-9R that was derived from
IL-3-dependent murine pro-B Ba/F3 cells as described [9]. 32D/9R
cells were generated by neomycin selection of 32D cells electroporated
with pEF-myc-cyto vector (Invitrogen), in which hIL-9R cDNA was
cloned into the NcoI and NotI restriction sites. 32D/9R/IRS cells were
generated by transfecting 32D/9R cells with pEF-BOS plasmid con-
taining the human cDNA for IRS1 (kindly provided by Dr. Renato
Baserga, Thomas Je¡erson University, PA, USA) followed by selec-
tion with puromycin.
2.3. Analysis of STAT and PKB phosphorylation, and inhibitor
treatment
Cells were washed with phosphate-bu¡ered saline, resuspended in
DMEM containing 0.5% bovine serum albumin, 20 mM HEPES, and
incubated for 6 h at 37‡C. Cells were stimulated in the same medium
(106 cells/ml), centrifuged and resuspended in 250 Wl of Laemmli bu¡-
er. 25 Wl was loaded on 8% pre-cast SDS^PAGE and analyzed by
Western blot using antibodies speci¢c for phospho-serine 473 (Bio-
source) or phospho-threonine 308 (New England Biolabs) of PKB, an
antibody speci¢c to phospho-tyrosine 705 of STAT3 (New England
Biolabs), or actin (Sigma). Both anti-phospho-PKB antibodies recog-
nize all three isoforms of PKB. To determine PI 3-K dependence of
PKB activation, TS1 cells were treated with 100 nM of either wort-
mannin or SB202190 (Calbiochem) for 4 h before cytokine stimula-
tion.
2.4. IRS2 and PI 3-K co-immunoprecipitation
TS1 and BaF/9R cells were washed and cytokine-starved for 6 h. 50
million cells were stimulated with 50 ng/ml of IL-9 or IL-4 for 15 min,
then washed and resuspended in lysis bu¡er (0.8% Brij96, 0.2% NP-
40, 50 mM Tris pH 8, 150 mM sodium chloride, 1 mM EDTA, 1 mM
sodium vanadate, 1 mM sodium £uoride, 1 mM PMSF, 10 Wg/ml
aprotinin and 10 Wg/ml leupeptin). After 10 min, lysates were centri-
fuged (13 000Ug). 5 Wg of anti-IRS2 antibody (Upstate Biotechnology
Inc.) was added to supernatant and incubated for 2 h. Lysates were
then incubated with protein-A-agarose overnight. The next day, beads
were washed and resuspended in Laemmli bu¡er and boiled. Proteins
were separated in a 6% SDS^PAGE gel (Novex) and analyzed by
Western blot using 1 Wg/ml of anti-phosphotyrosine 4G10, anti-p85/
PI 3-K or anti-IRS2 antibodies (Upstate Biotechnology Inc.) as
probes. Proteins were detected by chemiluminescence (ECL, Amer-
sham).
3. Results
3.1. IL-9 induces IRS2 phosphorylation and association to p85
PI 3-K subunit
TS1 is an IL-9-dependent T-helper cell line in which phos-
phorylation of IRS1 and IRS2 has been shown as a conse-
quence of IL-9 stimulation [14,20]. Since IRS1 and IRS2 can
associate with and activate PI 3-K upon insulin stimulation
[15], we addressed the possibility that IL-9-induced activation
of IRS1/2 may also lead to the formation of an IRS/PI 3-K
complex. As shown in Fig. 1, both IL-4 or IL-9 stimulation
resulted in the tyrosine phosphorylation of IRS2. In addition,
p85 was found to co-immunoprecipitate with the phosphory-
lated form of IRS2 after stimulation with either cytokine (Fig.
1). IL-4 and IL-9 also induced IRS2 phosphorylation and
association with p85 in Ba/F3 cells that were transfected
with the IL-9R (Fig. 1, right panels).
3.2. IL-9 induces PKB phosphorylation in TS1 cells but not in
BaF/9R, MC9 and Mo7e cells
As the IRS/p85 association has been shown to initiate a PI
3-K-dependent cascade, we tested the activation of PKB, a
major downstream e¡ector of PI 3-K. PKB phosphorylation
at serine 473 by PDK1 has been reported to be critical for the
activation of this kinase [17,21]. As shown in Fig. 2, treatment
of TS1 cells with either IL-4 or IL-9 led to the phosphoryla-
tion of this residue. To further con¢rm that the IL-9-induced
phosphorylation of PKB depends upon the activity of PI 3-K,
we used the PI 3-K inhibitor wortmannin. As shown in Fig. 2,
wortmannin completely inhibited the phosphorylation of
PKB, but not the phosphorylation of IRS1/2, after IL-9 or
IL-4 treatment of TS1 cells. The p38 mitogen-activated pro-
tein kinase (p38/MAPK) has also been shown to phosphory-
late serine 473 in vitro [21]. The p38/MAPK inhibitor
SB202190 did not a¡ect PKB and IRS2 phosphorylation,
demonstrating that p38/MAPK activity is not involved in
this pathway (Fig. 2).
Surprisingly, in BaF/9R cells, IL-9 treatment did not result
in phosphorylation of serine 473 of PKB (Fig. 3A), while IL-3
treatment did. Thus, IL-9-mediated IRS2 phosphorylation
and p85 recruitment were not su⁄cient to induce PKB phos-
phorylation in these cells. We also used two other cell lines
that proliferate in the presence of IL-9: the murine mast cell
line MC9 and the human megakaryocytic leukemia Mo7e
[1,22]. PKB phosphorylation was absent or barely detectable
in MC9 and Mo7e cells treated with IL-9, in contrast to cells
Fig. 1. IL-9 promotes IRS2 phosphorylation and recruitment of p85
PI 3-K subunit. TS1 and BaF/9R cells were cytokine-starved for 6 h
and restimulated for 10 min with IL-4 (50 ng/ml) or IL-9 (50
ng/ml), or left untreated. IRS2 was immunoprecipitated from lysates
using an anti-IRS2 antibody, and precipitated proteins were ana-
lyzed by Western blotting with anti-phosphotyrosine antibodies
(upper panels) to detect IRS2 phosphorylation, or with anti-p85. As
a control, membranes were reprobed with anti-IRS2 antibodies.
Similar results were obtained in at least two independent experi-
ments.
Fig. 2. PI 3-K-dependent phosphorylation of PKB by IL-9 in TS1
cells. TS1 cells were washed, starved for 6 h before stimulation with
IL-4 or IL-9. When indicated, cells were pretreated for 4 h with
wortmannin or SB202190 prior to stimulation. Total lysates were
analyzed by Western blot with antibodies speci¢c for phosphorylat-
ed serine 473 in PKB protein (upper panel) or with anti-phosphoty-
rosine antibodies (bottom panel). IRS1/2 proteins were identi¢ed as
the major phosphorylated 170 kDa species after cytokine stimula-
tion.
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treated with IL-3, IL-4 or SCF (Fig. 3B). Similar results were
obtained with antibodies recognizing the second important
phosphorylated site of PKB, threonine 308, which is the target
of an unidenti¢ed kinase referred to as PDK2 [17]. IL-9 in-
duced the phosphorylation of this site in TS1 cells, but not in
BaF/9R (data not shown). IL-9 activated STAT3 in all IL-9-
dependent cells tested. In conclusion, IL-9-induced cell growth
did not correlate with PKB phosphorylation.
3.3. Ectopic expression of IRS1 in 32D/9R cells causes
proliferation in response to IL-9
To further understand the role of IRS1/2 in IL-9-dependent
survival and proliferation, we used the IL-3-dependent murine
myeloid cell line 32D, which lacks endogenous IRS1 and IRS2
[13,23], and has undetectable levels of IL-9R (data not
shown). We transfected 32D cells with a hIL-9R expression
construct and analyzed the e¡ect of IL-9 on survival and
proliferation of these cells (32D/9R) in absence of IRS1/2.
As expected, parental 32D cells died even in the presence of
high concentrations of IL-9 (Fig. 4). In contrast, treatment of
32D/9R cells with IL-9 resulted in a dose-dependent survival,
but not cell growth. Hence, IRS1/2 is not required for IL-9-
induced survival of 32D/9R cells. FACS analysis con¢rmed
that the expression of IL-9R was comparable to the number
of receptors expressed in BaF/9R cells, which proliferate in
response to IL-9 [9], ruling out the possibility that a low
receptor density is the cause for the non-proliferative e¡ect
of IL-9 on 32D/9R cells (data not shown).
Subsequently, we explored the possibility that expression of
IRS1/2 in 32D/9R would result in the ability of IL-9 to induce
proliferation of these cells. We transfected 32D/9R cells with
an IRS1 expression vector and generated 32D/9R/IRS cells.
Three independent electroporations were performed after
which cells were maintained for 10 days in the presence of
IL-3 and puromycin for selection. Puromycin-resistant cells
were ¢rst tested for expression of IRS1 by Western blot
(Fig. 5A) and IRS1 expressing cells were used for proliferation
assays. Fig. 5B shows the e¡ect of IL-9 treatment on prolif-
eration of 32D/9R and 32D/9R/IRS cells. After 4 weeks, while
the number of 32D/9R cells had increased to only about
2-fold, 32D/9R/IRS cells had expanded to over 600-fold,
clearly demonstrating a positive e¡ect of IRS1 on IL-9-in-
duced proliferation. Noticeably, the proliferation rate of these
cells in response to IL-9 remained quite low as compared to
BaF/9R or TS1 cells.
Fig. 3. PKB is not signi¢cantly phosphorylated in BaF/9R, MC9
and Mo7e cells treated with IL-9. (A) Cytokine-starved BaF/9R
cells were restimulated with hIL-9 (100 ng/ml) for various periods
of time or with IL-3 for 10 min. PKB phosphorylation was ana-
lyzed as above by Western blotting (105 cells/well). Similar results
were obtained in three independent experiments. (B) The mast cell
line MC9 was washed, starved and stimulated for 10 min with mur-
ine IL-9 (20 ng/ml), IL-4 (20 ng/ml), or IL-3 (500 U/ml). The hu-
man leukemia Mo7e was treated similarly and stimulated with hIL-
9 or SCF (both at 100 ng/ml). Total lysates were analyzed by West-
ern blot with antibodies recognizing phospho-serine 473 of PKB,
phospho-threonine 308 of PKB, phospho-tyrosine 705 of STAT3, or
actin. The results shown are representative of at least two experi-
ments.
Fig. 4. 32D cells expressing IL-9R (32D/9R) survive in the presence
of IL-9. Cells were washed and treated with increasing concentra-
tions of hIL-9. After 48 h, the percentage of viable cell was mea-
sured by propidium iodide staining (125 Wg/ml) followed by FACS
analysis. In the presence of IL-3, viability of 32D and 32D/9R cells
was 90.7 þ 0.6% and 90.1 þ 0.3%, respectively. The data represent
the mean þ S.E.M. of triplicate samples. Similar results were ob-
tained with four independent clones.
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We next tested the activation of PKB in relation to IRS
expression after treatment of 32D/9R and 32D/9R/IRS1 cells
with IL-9. As expected, PKB was not phosphorylated upon
IL-9 stimulation of 32D/9R cells (Fig. 5C), suggesting that it
is not involved in IL-9-mediated survival. More surprisingly,
PKB phosphorylation was only slightly detectable in 32D/9R/
IRS1 cells treated with IL-9, based on the phosphorylation
state of serine 473 (Fig. 5C). Similar results were observed
when an antibody recognizing phospho-threonine 308 was
used (data not shown). In contrast, IL-3 treatment of 32D/
9R or 32D/9R/IRS1 cells produced a robust phosphorylation
of PKB at both residues. STAT3 was found activated by
either IL-9 or IL-3 in both cell lines, demonstrating that these
cells responded to the cytokine treatment. Taken together,
these data suggest that IRS1 expression promotes prolifera-
tion but is not su⁄cient to cause signi¢cant phosphorylation
of PKB in response to IL-9.
4. Discussion
The present data demonstrate that IRS1/2 adaptor proteins
play a prominent role in mediating the IL-9-induced prolifer-
ation in hemopoietic cells. This is based on the following
observations: (i) IRS1 and IRS2 are phosphorylated upon
IL-9 stimulation in various cell lines, (ii) 32D/9R cells, which
lack IRS1/2 expression, survive but do not proliferate in re-
sponse to IL-9, and (iii) IRS1 expression in these cells pro-
motes IL-9-induced proliferation. Interestingly, IRS2 phos-
phorylation by IL-4 in Ba/F3 cells is not enough to promote
proliferation in response to this cytokine (Fig. 1 and data not
shown). In line with this result, IL-9 poorly stimulates the
growth of Ba/F3 cells expressing a mutated IL-9R that does
no longer activate STAT proteins but still allowed IRS2 phos-
phorylation [9,12], indicating that IRS1/2 is not su⁄cient to
deliver a complete signal and that STAT function is necessary
to complement the IL-9-induced proliferative response [12].
Thus, IL-9-mediated signal transduction seems to rely both
on STAT and on IRS1/2 cascades to exert its e¡ect on pro-
liferation. IRS1 and IRS2 have both been shown to be im-
portant in the IL-4- and insulin-mediated proliferation and
appear to function interchangeably [13,23]. Although IL-2
and IL-3 can induce phosphorylation of IRS1/2 proteins
[24,25], IL-3-mediated proliferation of 32D cells does not re-
quire IRS1/2 activity and 32D cells expressing exogenous IL-
2RL can proliferate in response to IL-2 [26], thereby via an
IRS1/2-independent mechanism.
By contrast, survival of 32D/9R cells in the presence of IL-9
does not require IRS1/2 activation, although IRS1 is involved
in apoptosis inhibition by insulin and IL-4 in these cells and
various other models [27,28]. This is in line with our previous
¢ndings demonstrating that a constitutively active variant
of STAT5 is su⁄cient to prevent apoptosis of the BW5147
T-lymphoma cell line [10].
An important aspect of IRS1/2 function is its interaction
with the regulatory subunit of PI 3-K p85, which leads to
activation of PI 3-K and its downstream mediator PKB. In
this report, we show that IRS2 interacts with the p85 subunit
of PI 3-K and this event correlates with a wortmannin-sensi-
tive activation of PKB in TS1 cells. Remarkably, PKB phos-
phorylation upon IL-9 stimulation was barely detectable in
any of the other IL-9-dependent cell lines analyzed in this
study, although PKB could be activated by other cytokines.
These data suggest that PKB function is not required for IL-
9-dependent survival and proliferation. The cell-speci¢c, IL-9-
induced activation of PKB observed in TS1 cells may be the
result of growth selection. Indeed, TS1 cells were derived from
a T-helper clone that has been progressively selected for
growth in the presence of IL-9 [3]. This selection may have
altered the typical IL-9 signal transduction patterns.
Despite the fact that IRS1/2 appears implicated in the PI 3-
K-dependent activation of PKB [15], our data demonstrate
that activation of IRS1/2 does not always correlate with the
activation of PKB. Conversely, IL-3-induced activation of
PKB in 32D cells is PI 3-K-dependent but IRS1/2-indepen-
dent (Fig. 5C and [29]). The signaling events triggered by IL-9
Fig. 5. Ectopic IRS1 expression in 32D/9R cells promoted prolifera-
tion in response to IL-9. (A) Expression of IRS1 was analyzed in
32D/9R and 32D/9R/IRS1 clones (105 cells/well) by Western blot
with anti-IRS1 antibodies (UBI, 1 Wg/ml). (B) 32D/9R cells were
electroporated with an expression vector containing the IRS1 cDNA
or with a control empty vector. Cells were then maintained for 10
days in the presence of IL-3 and puromycin for selection. At day 0,
puromycin-resistant cells were washed and cultured in the presence
of hIL-9. After 4 weeks, the average number of cells ( þ S.E.M.)
from three independent transfections was obtained. No viable cells
were obtained in the absence of cytokine. (C) 32D/9R and 32D/9R/
IRS cells were cytokine-starved for 6 h in serum-free medium and
then restimulated for 15 min with the appropriate cytokines. West-
ern blots on total lysates were performed using antibodies against
the phosphorylated serine 473 residue of the PKB protein (upper
panel) or the phosphorylated tyrosine 705 residue of the STAT3
protein (lower panel). Detection of L-actin con¢rmed equal protein
loading (not shown). Similar results were obtained for three inde-
pendent clones in two independent experiments.
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downstream IRS1/2 still remain unknown. We failed to detect
association of SHP2 or GRB2 with IRS2 in response to IL-9
(data not shown). It is not clear whether IRS1/2-mediated IL-
9 function depends on PI 3-K activity. The PI 3-K inhibitor
LY294002 prevented the proliferation of BaF/9R cells that
were grown in the presence of either IL-3 or IL-9 (data not
shown). However, taking into account the many caveats asso-
ciated with the use of inhibitors for functional analyses, more
accurate studies using cells de¢cient in the di¡erent isoforms
of PI 3-K will be required to uncover putative novel IRS1/2-
dependent, PI 3-K-independent pathways that mediate cellu-
lar e¡ects triggered by IL-9.
In conclusion, our data suggest that IL-9-mediated survival
is independent of the phosphorylation PKB and IRS1/2, the
latter protein being involved in promoting proliferation. This
study also shows that p85 recruitment to IRS1/2 is not su⁄-
cient for PKB phosphorylation.
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